Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kenya KusunoseTakumi ImaiAtsushi TanakaKaoru DohiKazuki ShiinaTakahisa YamadaKeisuke KidaKazuo EguchiHiroki TeragawaYasuchika TakeishiNobuyuki OhteHirotsugu YamadaMasataka SataKoichi Nodenull nullPublished in: Cardiovascular diabetology (2021)
In the subgroup with a lower LV diastolic function, canagliflozin showed a trend of reduced NT-pro BNP levels compared to that observed with glimepiride. This study suggests that the beneficial effects of canagliflozin treatment may be different in subgroups classified by the severity of LV diastolic dysfunction.
Keyphrases
- left ventricular
- ejection fraction
- hypertrophic cardiomyopathy
- aortic stenosis
- blood pressure
- cardiac resynchronization therapy
- acute myocardial infarction
- heart failure
- mitral valve
- phase iii
- left atrial
- oxidative stress
- clinical trial
- study protocol
- open label
- coronary artery disease
- aortic valve
- smoking cessation
- percutaneous coronary intervention
- randomized controlled trial
- transcatheter aortic valve replacement